Inlicensing The General Manager of OBI Pharma, a biopharmaceutical company currently working on a breast cancer drug, offers perspectives on developing a successful biotech company in Taiwan, the overall drug development ecosystem in Taiwan, and the acquire-develop-transfer model of doing business. Throughout our interviews in Taiwan, several industry stakeholders have expressed…
investment Cormac Callaghan, founder and managing director of Primecore, a portfolio and program management consultancy based in Dublin and Cambridge, Massachusetts, has managed large-scale change programs for the pharmaceutical industry for the better part of 30 years. He has seen his share of setbacks: between 2006 and 2008, Callaghan was the…
BCF Business Law Gino Martel explains the present environment for M&As, divestitures and out-licensing in the Canadian biotech sector, the different ways that biotech companies can commercialize their scientific successes in the current market climate, and strategies for keep scientific talent in Canada. How do mergers and acquisitions in the pharmaceutical industry in…
Biotech City The director of Biotech City in Laval, close to Montreal, discusses the advantages brought on by the cluster effect, and how this has played out at Biotech City, a government funded cluster of 80 companies and over 5,000 employees. Your background has a strong focus on business start-ups and development,…
Biotechnology The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s to a niche disease, AA amyloidosis, as well as the strategic shift towards becoming a semi-virtual model company. He also considers the importance of creating global links to capital as a…
Basic Research A leading figure in the Taiwanese pharmaceutical sector, Lee divulges the practicalities behind ECFA, the free trade agreement that was signed between China and Taiwan in 2010 but has not yet come into full force; questions whether a lack of multinational investment has been a major disadvantage for Taiwan; explains…
JHL Biotech Dr. Karen Wen of Mycenax likened her company to a “kitchen.” Would you say the same of JHL? Racho Jordanov (RJ): We might indeed liken ourselves to a kitchen. But I would add this: there are a lot of cookbooks out there, but…
Biotech As in many emerging countries, it is taking a while for Mexican legislation to catch up with the latest technologies. Alejandra Mendoza, general manager of Genzyme Mexico, says that regulation has been the main challenge her firm has had to face. “We were pioneers in biotech in Mexico, so we…
Ausbiotech What have been the focus areas for the association in improving the wellbeing of the life science biotech industry and what have been the key milestones/achievements since 2008 in providing representation and services to promote the global growth of Australian biotechnology? In addition to the financial crisis the government decided…
ireland Mr. Mazeman, can you please begin by offering a brief overview of your career to date? I am a French pharmacist by training, with expertise in pharmacology. I have worked for Servier for my entire career. I started in the industry as a medical representative for the company. I went…
China One of the earliest innovative biotech companies in China, Zensun has developed what its founder Dr. Zhou Mingdong calls a rare made-in-China first-in-class therapeutic candidate, Neucardin®, which has been shown to improve cardiac function, quality of life and exercise capability, and, to reduce all-cause mortality rates in certain patients suffering…
Biotech Pharmaceutical Co Ltd Could you please introduce the history and main characteristics of Biotech Pharmaceutical? Biotech Pharmaceutical was established in the year 2000, so we are a relatively young company for biopharmaceutical products by Chinese standards. However, we were the first company in China to discover, develop, manufacture and market monoclonal antibodies. Before…
See our Cookie Privacy Policy Here
